Recent News Pacira BioSciences Announces Positive Topline Data from Phase 3 Study of EXPAREL as a Single-dose Sciatic Nerve Block in the Popliteal Fossa for Bunionectomy 09/21/22 Pacira Receives Positive CHMP Opinion for EXPAREL® for the Treatment of Postsurgical Pain in Children Aged 6 or Older 09/20/22 Pacira BioSciences Reports Preliminary Net Product Sales of $59.1 Million for August 2022 09/13/22 Pacira BioSciences Announces Positive Topline Data from Phase 3 Study of EXPAREL as a Single-dose Femoral Nerve Block in the Adductor Canal for Total Knee Arthroplasty 09/07/22 Pacira BioSciences Reports Preliminary Net Product Sales of $50.2 Million for July 2022 08/10/22 Browse the press release archive
